Thursday, June 11

Browsing: LAmBC

Treatments

Giredestrant Plus Palbociclib Shows Numerical PFS Gain in ER+, HER2– LA/mBC

By NewsCancerJune 2, 20260

Primary findings from the phase 3 persevERA BC trial (NCT04546009) evaluating first-line giredestrant plus palbociclib vs letrozole plus palbociclib in…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Woman who has endured three cancers completes 141-hill challenge

Boy whose cancer returned two weeks after remission gets new hope from trial

CFTR-driven immune microenvironment reprogramming synergizes with anti-PD-L1 antibody in hepatocellular carcinoma

Browsing: LAmBC

Giredestrant Plus Palbociclib Shows Numerical PFS Gain in ER+, HER2– LA/mBC

Woman who has endured three cancers completes 141-hill challenge

Boy whose cancer returned two weeks after remission gets new hope from trial

CFTR-driven immune microenvironment reprogramming synergizes with anti-PD-L1 antibody in hepatocellular carcinoma

74 Real-World Study Characterizing Patient Characteristics, Treatments, and Unmet Need in IO-Ineligible Patients With Metastatic Triple-Negative Breast Cancer

Woman who has endured three cancers completes 141-hill challenge

Boy whose cancer returned two weeks after remission gets new hope from trial

CFTR-driven immune microenvironment reprogramming synergizes with anti-PD-L1 antibody in hepatocellular carcinoma

74 Real-World Study Characterizing Patient Characteristics, Treatments, and Unmet Need in IO-Ineligible Patients With Metastatic Triple-Negative Breast Cancer

Latest Post

Woman who has endured three cancers completes 141-hill challenge

Boy whose cancer returned two weeks after remission gets new hope from trial

CFTR-driven immune microenvironment reprogramming synergizes with anti-PD-L1 antibody in hepatocellular carcinoma

Subscribe to Updates

What's Hot

Browsing: LAmBC